Elif Er Gülbezer
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Elif Er Gülbezer has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Adil Özcanlı
Department of Dermatology and Venerology Koç University School of Medicine İstanbul Turkey
1 shared publication- Alessandra Vultaggio
Immunoallergology Unit, Careggi University Hospital, 50134 Florence, Italy
1 shared publication - Betül Özdel Öztürk
Department of Immunology and Allergic Diseases, Ankara Bilkent City Hospital, 06800 Ankara, Turkey
1 shared publication - Burcu Barutçuoğlu
Department of Medical Biochemistry, Faculty of Medicine, Ege University, İzmir, Turkiye
1 shared publication - Defne Özkoca
Department of Dermatology and Venereology, Başakşehir Çam and Sakura City Hospital, İstanbul, Türkiye
1 shared publication - Deniz Güllü
Koç University School of Medicine, Istanbul, Turkey; Koç University-Isbank Center for Infectious Diseases, Istanbul, Turkey; Koç University Graduate School of Health Sciences, Istanbul, Turkey
1 shared publication
Latest Publications
- Open Access
- 12 May 2026
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 13 (2) , 1-3
Atypical Neurological Presentation of Familial Mediterranean Fever Mimicking Refractory Childhood Epilepsy
Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder classically characterized by recurrent episodes of fever and polyserositis. Although central nervous system involvement is rare, FMF can atypically present with severe neurological manifestations, including seizure disorders. The authors report the highly unusual case of a 27-year-old male who was misdiagnosed with West syndrome at 8 months of age and was subsequently treated with multiple antiepileptic drugs (AEDs) for over 2 decades. The patient was initially referred for the evaluation of chronically elevated C-reactive protein (CRP) and serum amyloid A (SAA) levels of unknown etiology. A detailed medical history revealed recurrent episodes of paradoxical abdominal pain. Genetic analysis identified heterozygous R202Q and M680I mutations in the MEFV gene, establishing the diagnosis of FMF. Strikingly, the initiation of targeted autoinflammatory therapy with colchicine not only normalized his systemic inflammatory markers but also resulted in complete seizure freedom. This profound clinical response enabled the successful withdrawal of his long-term AED polytherapy. This case highlights that refractory, childhood-onset epilepsy can occasionally serve as an atypical neurological mask for FMF. Clinicians must consider autoinflammatory etiologies in patients with treatment-resistant seizures and unexplained systemic inflammation, as targeted therapy can safely reverse years of unnecessary antiepileptic treatment. Cite this article as: Berkkan M, Er Gülbezer, E. Atypical neurological presentation of familial Mediterranean fever mimicking refractory childhood epilepsy. Eur J Rheumatol. 2026, 13(2), 0027, doi:10.5152/eurjrheum.2026.26027.
- 12 May 2026
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 13 (2) , 1-3
Open AccessAtypical Neurological Presentation of Familial Mediterranean Fever Mimicking Refractory Childhood Epilepsy
Familial Mediterranean fever (FMF) is a monogenic autoinflammatory disorder classically characterized by recurrent episodes of fever and polyserositis. Although central nervous system involvement is rare, FMF can atypically present with severe neurological manifestations, including seizure disorders. The authors report the highly unusual case of a 27-year-old male who was misdiagnosed with West syndrome at 8 months of age and was subsequently treated with multiple antiepileptic drugs (AEDs) for over 2 decades. The patient was initially referred for the evaluation of chronically elevated C-reactive protein (CRP) and serum amyloid A (SAA) levels of unknown etiology. A detailed medical history revealed recurrent episodes of paradoxical abdominal pain. Genetic analysis identified heterozygous R202Q and M680I mutations in the MEFV gene, establishing the diagnosis of FMF. Strikingly, the initiation of targeted autoinflammatory therapy with colchicine not only normalized his systemic inflammatory markers but also resulted in complete seizure freedom. This profound clinical response enabled the successful withdrawal of his long-term AED polytherapy. This case highlights that refractory, childhood-onset epilepsy can occasionally serve as an atypical neurological mask for FMF. Clinicians must consider autoinflammatory etiologies in patients with treatment-resistant seizures and unexplained systemic inflammation, as targeted therapy can safely reverse years of unnecessary antiepileptic treatment. Cite this article as: Berkkan M, Er Gülbezer, E. Atypical neurological presentation of familial Mediterranean fever mimicking refractory childhood epilepsy. Eur J Rheumatol. 2026, 13(2), 0027, doi:10.5152/eurjrheum.2026.26027.
- Open Access
- 29 August 2025
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 42 (6) , 574-576
Misdiagnosed Lyme: A Multidisciplinary Case Series from a Non- Endemic Region
- 29 August 2025
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 42 (6) , 574-576
Open AccessMisdiagnosed Lyme: A Multidisciplinary Case Series from a Non- Endemic Region
- 24 March 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1708-1710
Association Between Familial Inflammatory Diseases and Hidradenitis Suppurativa Severity: A Single‐Center Study
- 24 March 2025
- Published by Wiley in International Journal of Dermatology
- Vol. 64 (9) , 1708-1710
Association Between Familial Inflammatory Diseases and Hidradenitis Suppurativa Severity: A Single‐Center Study
- Open Access
- 9 September 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (3) , 474-483
Prevalence of metabolic syndrome patıents with systemic sclerosis
Objective: To determine the prevalence of metabolic syndrome (MetS) in Turkish systemic sclerosis (SSc) patients. Materials and Methods: In this cross-sectional, single-centre study, 76 SSc patients admitted to the outpatient clinic of our tertiary care hospital between July and September 2021 were included. The National Cholesterol Education Programme's Adult Treatment Panel (NCEP-ATP III) criteria were used to define metabolic syndrome (MetS). The relationship between MetS and SSc organ involvement and disease characteristics was investigated. Results: According to the ATP III criteria, 37 cases (48.7%) were identified as having MetS. The prevalance of MetS increased with advancing age (40-45 years: 25%, 46-60 years: 48.4%, >60 years: 62.9%). The cases were divided into two groups according to the presence or absence of MetS. Patients with MetS had higher mean age (58.2±9.4 vs. 51.6±13.5, p=0.015) and lower modified Rodnan skin scores (14 vs. 22, p=0.019). The groups were comparable regarding disease subtype, duration and activity, organs/systems involved and disease-related damage. Conclusion: Although the prevalence of MetS in SSc patients in our study was higher than that observed in the general population of our country, the prevalence of MetS did not increase when compared to the similar age group. MetS was thought to be related to age and gender predominance rather than the disease itself. Although mRSS was found to be significantly lower in patients with MetS, its sensitivity to predict MetS was found to be low. Nevertheless, our data suggest that the risk of MetS should be considered in SSc patients.
- 9 September 2024
- Published by Ege Journal of Medicine in Ege Tıp Dergisi
- Vol. 63 (3) , 474-483
Open AccessPrevalence of metabolic syndrome patıents with systemic sclerosis
Objective: To determine the prevalence of metabolic syndrome (MetS) in Turkish systemic sclerosis (SSc) patients. Materials and Methods: In this cross-sectional, single-centre study, 76 SSc patients admitted to the outpatient clinic of our tertiary care hospital between July and September 2021 were included. The National Cholesterol Education Programme's Adult Treatment Panel (NCEP-ATP III) criteria were used to define metabolic syndrome (MetS). The relationship between MetS and SSc organ involvement and disease characteristics was investigated. Results: According to the ATP III criteria, 37 cases (48.7%) were identified as having MetS. The prevalance of MetS increased with advancing age (40-45 years: 25%, 46-60 years: 48.4%, >60 years: 62.9%). The cases were divided into two groups according to the presence or absence of MetS. Patients with MetS had higher mean age (58.2±9.4 vs. 51.6±13.5, p=0.015) and lower modified Rodnan skin scores (14 vs. 22, p=0.019). The groups were comparable regarding disease subtype, duration and activity, organs/systems involved and disease-related damage. Conclusion: Although the prevalence of MetS in SSc patients in our study was higher than that observed in the general population of our country, the prevalence of MetS did not increase when compared to the similar age group. MetS was thought to be related to age and gender predominance rather than the disease itself. Although mRSS was found to be significantly lower in patients with MetS, its sensitivity to predict MetS was found to be low. Nevertheless, our data suggest that the risk of MetS should be considered in SSc patients.